Matteo Carlino is a Medical Oncologist at Westmead and Blacktown Hospitals, a Clinical Senior Lecturer at The University of Sydney, and a Faculty Member at MIA. He has recently completed a PhD examining predictors of response and mechanisms of resistance to BRAF and MEK inhibitor treated melanoma.

He continues to be involved in the translational research program based at MIA and the Westmead Institute for Cancer Research. He is an investigator on multiple Phase I,II and III clinical trials in melanoma targeted and immunotherapy.